China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class ASZSE: 000999

China Resources Sanjiu Medical & Pharmaceutical Co: Revenue and profit declined, but asset growth and Tasly integration drive future potential

· Issued by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A

Q1 2025 revenue and net profit declined year-over-year, but operating cash flow and total assets grew, driven by the Tasly acquisition. The company faces a challenging market but is leveraging new synergies and focusing on innovation for long-term growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A

All China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A news releases